Ovid Therapeutics announces the first ever sponsored clinical trial for Angelman Syndrome. You first heard about Gabaxadol from Dr. Matthew During at the FAST 2014 Summit, now we have the exciting news that this sponsored clinical trial is moving forward. “We very much look forward to moving OV101 into the clinic, and hopefully making a difference in the lives of those with Angelman Syndrome and their families,» stated Dr. Matthew During, President and Chief Scientific Officer of Ovid. Read more about this announcement here…